How does Inventera drive innovation?

Inventera drives innovation by connecting research, development, and applications based on its nanomedicine platform.

How is Inventera different from a typical biotech company?

Inventera uses a platform-based approach rather than a single product, enabling expansion into diverse diagnostic and therapeutic applications.

What competitive strengths is Inventera building?

Inventera builds sustainable competitiveness as a nanomedicine platform company by linking core science, clinical validation, and commercialization partnerships.

We Are Inventera

We use breakthrough science

to solve unmet medical needs,

translate it into solutions,

and bring them to market.

Invent, Develop, Commercialize & Expand

Our Formula for Innovation

Mission

We invent and deliver innovative diagnostic and therapeutic

solutions through our nanoscience technology and expertise.

Vision

To become a global nanomedicine leader

spanning both diagnostics and therapeutics.

Core Values

Unmet Needs–Driven Novelty

Start with the unmet medical needs. We define the problem clearly and invent practical solutions.

Feasibility

Invent to reach the market. We develop nanomedicines with commercialization in mind.

Versatility

One platform, numerous possibilities. We continuously expand our pipelines and build a scalable foundation for long-term growth.

CEO Message

A Promise Written in Innovation

Inventera was founded in November 2018 to develop innovative diagnostic and therapeutic solutions.

The name Inventera carries multiple meanings: Invent + Therapy (from invention to therapy), Invent + Tera (10¹²) (the number of possibilities), and inspiration from the French word inventera ("will invent"). Together, they reflect our commitment to advancing healthcare through continuous technological invention.

At Inventera, we believe that what matters as much as great technology is the ability to bring it into the real world. Innovation shouldn't stop in the lab. Our goal is to invent with scientific insight, validate through development and data, and complete the journey with solutions that perform in real clinical and market settings.

Guided by this mindset, we are advancing toward the commercialization of a global first-in-class nanomedicine by 2027. This milestone will serve as a critical starting point-validating the potential of our platform technology and enabling expansion into broader indications and pipelines.

Moving forward, Inventera will continue to grow into a leading global nanomedicine company by expanding pipelines across diagnostics and therapeutics.

Tae-Hyun Shin, Founder · CEO · CTO, Inventera Inc.

The Beginning